circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-08. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Lenin was immediately committed to avoid antagonising the peasantry by making efforts to coax them away from the Socialist Revolutionaries, allowing a peasant takeover of nobles' estates while no immediate nationalisations were enacted on peasants' property. The Decree on Land (8 November 1917) fulfilled Lenin's promised redistribution of Russia's arable land to the peasants, who reclaimed their farmlands from the aristocrats, ensuring the peasants' loyalty to the Bolshevik party. To overcome the civil war's economic interruptions, the policy of War Communism (1918–1921), a regulated market, state-controlled means of distribution and nationalisation of large-scale farms, was adopted to requisite and distribute grain in order to feed industrial workers in the cities whilst the Red Army was fighting the White Army's attempted restoration of the Romanov dynasty as absolute monarchs of Russia. Moreover, the politically unpopular forced grain-requisitions discouraged peasants from farming resulted in reduced harvests and food shortages that provoked labour strikes and food riots. In the event, the Russian peoples created an economy of barter and black market to counter the Bolshevik government's voiding of the monetary economy. In 1921, the New Economic Policy restored some private enterprise to animate the Russian economy.
== Early life and career == Reid, who originally played football for the North Balwyn Methodists, played two senior games for Hawthorn in the 1966 VFL season and one further game the following year. Reid was a member of Preston's 1968 and 1969 Victorian Football Association premiership teams. Having graduated from university with a medical degree while at Preston, Reid worked as a club doctor with Richmond from 1976 to 1979.
=== Anesthesia === To induce general anesthesia, propofol is the drug used almost exclusively, having largely replaced sodium thiopental. It is often administered as part of an anesthesia maintenance technique called total intravenous anesthesia, using either manually programmed infusion pumps or computer-controlled infusion pumps in a process called target controlled infusion (TCI). Propofol is also used to sedate people who are receiving mechanical ventilation but not undergoing surgery, such as patients in the intensive care unit. In critically ill patients, propofol is superior to lorazepam both in effectiveness and overall cost. Propofol is relatively inexpensive compared to medications of similar use due to shorter ICU stay length. One of the reasons propofol is thought to be more effective (although it has a longer half-life than lorazepam) is that studies have found that benzodiazepines like midazolam and lorazepam tend to accumulate in critically ill patients, prolonging sedation. Propofol has also been suggested as a sleep aid for critically ill adults in an ICU setting; however, its effectiveness in replicating the mental and physical aspects of sleep for people in the ICU is unclear. Propofol can be administered via a peripheral IV or central line. Propofol is often paired with fentanyl (for pain relief) in intubated and sedated people. The two drugs are molecularly compatible in an IV mixture form. Propofol is also used to deepen anesthesia to relieve laryngospasm. It may be used alone or followed by succinylcholine.
Elongation depends on elongation factors. At the end of the initiation step, the mRNA is positioned so that the next codon can be translated during the elongation stage of protein synthesis. The initiator TRNA occupies the P site in the ribosome, and the A site is ready to receive an aminoacyl-TRNA. During chain elongation, each additional amino acid is added to the nascent polypeptide chain in a three-step micro cycle. The steps in this micro cycle are (1) positioning the correct aminoacyl-TRNA in the A site of the ribosome, which is brought into that site by eEF1, (2) forming the peptide bond, and (3) shifting the mRNA by one codon relative to the ribosome with the help of eEF2. Unlike bacteria, in which translation initiation occurs as soon as the 5' end of an mRNA is synthesized, in eukaryotes, such tight coupling between transcription and translation is not possible because transcription and translation are carried out in separate compartments of the cell (the nucleus and cytoplasm). Eukaryotic mRNA precursors must be processed in the nucleus (e.g., capping, polyadenylation, splicing) in ribosomes before they are exported to the cytoplasm for translation. Translation can also be affected by ribosomal pausing, which can trigger endo nucleolytic attack of the TRNA, a process termed mRNA no-go decay. Ribosomal pausing also aids co-translational folding of the nascent polypeptide on the ribosome, and delays protein translation while it is encoding TRNA. This can trigger ribosomal frameshifting.
Polylactic acid (PLA) is a synthetic biodegradable polymer widely used as a dermal filler for soft tissue augmentation, classified into two stereoisomeric forms: poly(L-lactic acid) (PLLA) and poly(D,L-lactic acid) (PDLLA), both of which are widely used as dermal fillers, though variations in their physicochemical properties may lead to differences in handling characteristics and clinical performance. Unlike hyaluronic acid fillers that provide immediate volume, PLLA particles remaining after carrier absorption are degraded into lactic acid, which enhances collagen synthesis by fibroblasts, while immune cells recognize PLLA as a foreign body, initiating macrophage recruitment that induces fibroblast recruitment and fibrotic tissue formation.
Sources: en.wikipedia.org
=== Removal of the smear layer and dentine etching === A dentine conditioning agent is used initially, to remove the smear layer resulting from the preparation of a cavity and, to alter the dentine surface by partially demineralising the intertubulary dentine. This partially demineralised dentine acts as a hollow scaffolding which can be perfused with the primer. Over-etching (as well as over-drying) of the dentine can lead to collapse of the collagen network, making infiltration of the primer more challenging. However, sclerosed dentine requires a longer time of exposure to the dentine conditioner compared to healthy dentine. Some dentine conditioners contain a chemical called glutaraldehyde, which reinforces the collagen matrix, preventing its collapse. Some common dentine conditioners include:
== Early life and education == Vale was born on 26 October 1908 (one of 12 children) in Toora, Victoria, a small farming community in South Gippsland, Victoria, Australia. Vale's parents and siblings lived on an estate at Tarwin Meadows, a large dairy property with 1,000 cows, for which his father was a bookkeeper. He attended school at Tarwin Meadows, finishing in the 8th grade at 14 years of age and obtaining his merit certificate with a high rating.
Lectins are carbohydrate-binding proteins that are highly specific for sugar groups that are part of sugars and other molecules. Lectins can recognize specific types of sugar moieties and play a role in the recognization of carbohydrates and glycosylated proteins. This recognition is used within organisms to mediate binding between specific cell types, to recognize chemical messages, and to recognize foreign cells: for example, the human lectin CLEC11A conveys a signal for bone growth. Lectins are also used by pathogens such as bacteria, viruses, and fungi to recognize and tightly attach to their host cells. Because lectin binds sugar moieties, it can "glue" together entities that have similar sugar moieties. Many cells have specific types of surface glycans; when a lectin is added, they become glued together or agglutinated. Glycoconjugates and polysaccharides that share similar moieties can likewise be glued together, making them precipitate out of a solution. By using the correct lectin, one can separate out entities that have a certain sugar moiety. This is useful for the determination of blood type and separating cells by type. Because a lectin molecule can only bind a handful of sugar groups, it can be disabled by an excess of the sugar group that it recognizes. Lectins are found in all domains and kingdoms of life, from the prokaryotes to the eukaryotes, from the plants to the animals.
Amadori rearrangement Carbohydrate acetalisation Carbohydrate digestion Cyanohydrin reaction Koenigs–Knorr reaction Lobry de Bruyn–Van Ekenstein transformation Nef reaction Wohl degradation Tipson-Cohen reaction Ferrier rearrangement Ferrier II reaction Related topics
Sources: en.wikipedia.org
==== Plasmid delivery ==== Individual genes can be inserted into specific sites on plasmids, and recombinant plasmids can be introduced into living cells. A method using macro-branched TAT has been proposed for plasmid DNA delivery into various cell lines and showed significant transfection capabilities. Multimers of TAT have been found to increase transfection efficiency of plasmid DNA by 6-8 times more than poly-L-arginine or mutant TAT2-M1, and by 390 times compared with the standard vectors.
There are many different biosynthesis pathways to ascorbic acid in plants. Most proceed through products of glycolysis and other metabolic pathways. For example, one pathway uses plant cell wall polymers. The principal plant ascorbic acid biosynthesis pathway seems to be via l-galactose. The enzyme l-galactose dehydrogenase catalyzes the overall oxidation to the lactone and isomerization of the lactone to the C4-hydroxyl group, resulting in l-galactono-1,4-lactone. l-Galactono-1,4-lactone then reacts with the mitochondrial flavoenzyme l-galactonolactone dehydrogenase to produce ascorbic acid. l-Ascorbic acid has a negative feedback on l-galactose dehydrogenase in spinach. Ascorbic acid efflux by embryos of dicot plants is a well-established mechanism of iron reduction and a step obligatory for iron uptake. All plants synthesize ascorbic acid. Ascorbic acid is a cofactor for enzymes involved in photosynthesis, synthesis of plant hormones, as an antioxidant and regenerator of other antioxidants. Plants use multiple pathways to synthesize vitamin C. The major pathway starts with glucose, fructose or mannose (all simple sugars) and proceeds to l-galactose, l-galactonolactone and ascorbic acid. This biosynthesis is regulated following a diurnal rhythm. Enzyme expression peaks in the morning to supporting biosynthesis for when mid-day sunlight intensity demands high ascorbic acid concentrations.
=== Etymology === The word "glaucoma" comes from the Ancient Greek γλαύκωμα, a derivative of γλαυκός (glaukos), which commonly described the color of eyes which were not dark (i.e. blue, green, light gray). Eyes described as γλαυκός due to disease might have had a gray cataract in the Hippocratic era, or, in the early Common Era, the greenish pupillary hue sometimes seen in angle-closure glaucoma. This colour is reflected in the Chinese word for glaucoma, 青光眼 (qīngguāngyǎn), literally "cyan-light eye". An alternative hypothesis connects the name to the Ancient Greek noun for 'owl', γλαύξ or γλαῦξ (both glaux).
Surimi: Surimi and surimi-based products are an example of value added products. Surimi is prepared from the mechanically deboned, washed (bleached) and stabilised flesh of fish. "It is an intermediate product used in the preparation of a variety of ready to eat seafood such as kamaboko, fish sausage, crab legs and imitation shrimp products. Surimi-based products are gaining more prominence worldwide, because of the emergence of Japanese restaurants and culinary traditions in North America, Europe and elsewhere. Ideally, surimi should be made from low-value, white fish with excellent gelling ability and which are abundant and available year-round. At present, Alaskan pollack accounts for a large proportion of the surimi supply. Other species, such as sardine, mackerel, barracuda, striped mullet have been successfully used for surimi production." Fishmeal and fish oil: "A significant proportion of the world catch (20 percent) is processed into fishmeal and fish oil. Fishmeal is a ground solid product that is obtained by removing most of the water and some or all of the oil from fish or fish waste. This industry was launched in the 19th century, based mainly on surplus catches of herring from seasonal coastal fisheries to produce oil for industrial uses in leather tanning and in the production of soap, glycerol and other non-food products. Presently, it uses small oily fish to produce fishmeal and oil. It is worthy to mention that, only where it is uneconomic or impracticable for human consumption, should the catch be reduced to fishmeal and oil.
November 14, 2008: Hong Kong Hong Kong becomes the second Asian economy to tip into recession, its exports hit by weakening global demand. Third-quarter GDP drops a seasonally adjusted 0.5% after a 1.4% fall in the previous quarter.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.